Literature DB >> 18441731

Oocyte cryopreservation in a woman with mosaic Turner syndrome: a case report.

Shahryar K Kavoussi1, Senait Fisseha, Yolanda R Smith, Gary D Smith, Gregory M Christman, L April Gago.   

Abstract

BACKGROUND: Turner syndrome (TS) is the most common sex chromosome anomaly. Spontaneous pregnancies have been reported in a small percentage of women with TS, particularly those with mosaicism. However, due to accelerated follicular atresia, the majority of TS patients undergo ovarian failure prior to or around the time of puberty. In vitro fertilization with donor oocytes and subsequent embryo transfer has been the predominant fertility option for such patients. We report a case of oocyte cryopreservation for a patient with mosaic TS including the evaluation, treatment decisions and ovarian response. CASE: A 28-year-old woman with mosaic TS and oligomenorrhea chose oocyte cryopreservation for fertility preservation. Ovarian reserve testing revealed a day 3 FSH of 4.3 mIU/mL and an antral follicle count of 40. She underwent controlled ovarian stimulation and had a vigorous response to a gonadotropin/gonadotropin-releasing hormone antagonist protocol, with a peak estradiol level of 4507 pg/mL. Transvaginal oocyte retrieval produced 15 oocytes, 13 of which met the criteria for vitrification.
CONCLUSION: Oocyte cryopreservation offers TS patients a new option to preserve future fertility; however, this new technology requires extensive counseling regarding not only its investigational nature but also risks specific to it and implications for this patient population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18441731

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  7 in total

Review 1.  Fertility Preservation in Women with Turner Syndrome: A Comprehensive Review and Practical Guidelines.

Authors:  Kutluk Oktay; Giuliano Bedoschi; Karen Berkowitz; Richard Bronson; Banafsheh Kashani; Peter McGovern; Lubna Pal; Gwendolyn Quinn; Karen Rubin
Journal:  J Pediatr Adolesc Gynecol       Date:  2015-10-17       Impact factor: 1.814

2.  Nonmalignant diseases and treatments associated with primary ovarian failure: an expanded role for fertility preservation.

Authors:  Jennifer Hirshfeld-Cytron; Clarisa Gracia; Teresa K Woodruff
Journal:  J Womens Health (Larchmt)       Date:  2011-08-09       Impact factor: 2.681

3.  First live birth after fertility preservation using vitrification of oocytes in a woman with mosaic Turner syndrome.

Authors:  L Strypstein; E Van Moer; J Nekkebroeck; I Segers; H Tournaye; I Demeestere; M-M Dolmans; W Verpoest; M De Vos
Journal:  J Assist Reprod Genet       Date:  2022-02-05       Impact factor: 3.412

Review 4.  Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).

Authors:  Antonio La Marca; Elisa Mastellari
Journal:  J Assist Reprod Genet       Date:  2021-01-25       Impact factor: 3.412

5.  Mouse oocyte vitrification with and without dimethyl sulfoxide: influence on cryo-survival, development, and maternal imprinted gene expression.

Authors:  Clementina Cantatore; Jenny S George; Raffaella Depalo; Giuseppe D'Amato; Molly Moravek; Gary D Smith
Journal:  J Assist Reprod Genet       Date:  2021-05-22       Impact factor: 3.357

6.  The use of oocyte cryopreservation for fertility preservation in patients with sex chromosome disorders: a case series describing outcomes.

Authors:  Rachel A Martel; Jennifer K Blakemore; M Elizabeth Fino
Journal:  J Assist Reprod Genet       Date:  2022-03-23       Impact factor: 3.357

7.  International consensus: ovarian tissue cryopreservation in young Turner syndrome patients: outcomes of an ethical Delphi study including 55 experts from 16 different countries.

Authors:  M J Schleedoorn; B H Mulder; D D M Braat; C C M Beerendonk; R Peek; W L D M Nelen; E Van Leeuwen; A A E M Van der Velden; K Fleischer; On Behalf Of The Turner Fertility Expert Panel
Journal:  Hum Reprod       Date:  2020-05-01       Impact factor: 6.918

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.